Patients

Bladder diseases affect more than 60 million patients in the U.S.

TARIS is committed to significantly improving the lives of patients with serious bladder conditions. We do this by developing therapies designed to treat disease more effectively than existing treatment options, and by reducing the patient burden with more convenient use. Our targeted therapies treat patients continuously so they can focus on living, not managing their disease.

• Disease Areas •

Voiding Dysfunction

Voiding dysfunction disrupts the bladder’s ability to store and eliminate urine. The most common form of voiding dysfunction is overactive bladder (OAB), which affects roughly 1 in 6 American adults.

OAB is characterized by increased urinary urgency and frequency, often with associated incontinence. These symptoms significantly limit patients’ daily activities and impair their quality of life. While OAB symptoms can result from an underlying neurologic injury, in most cases the cause is unclear.

Billions of dollars are spent annually on medications, surgical treatments, undergarments and behavioral modifications to manage OAB patients’ symptoms. For the majority of patients, these options do not sufficiently control their disease, and often have treatment-limiting side effects. A significant need exists for better, more patient-friendly therapies.

Muscle-Invasive Bladder Cancer

Bladder cancer is one of the most common malignancies in industrialized countries, affecting roughly 2.7 million people worldwide. In the U.S., the National Cancer Institute estimates approximately 81,000 new cases and over 17,000 deaths in 2018. Muscle-invasive bladder cancer (MIBC) accounts for 20-25 percent of newly diagnosed cases and the large majority of disease-related mortality.

Potentially curative treatments include radical cystectomy (surgical removal of the bladder) and/or chemo-radiation. These therapies are invasive, life altering and profoundly burdensome. Furthermore, people with bladder cancer are generally of advanced age and often suffer from underlying comorbidities. As a result, 40 percent or more of U.S. patients with MIBC are either unfit to undergo today’s potentially curative procedures or opt to not receive them.

• Clinical Trials •

Patients are critical stakeholders in the research and development of new medicines for any disease. TARIS conducts clinical trials to evaluate the safety and efficacy of its investigational therapies for urologic conditions. We invite patients to learn more about participating in our trials.

Muscle-Invasive Bladder Cancer

TAR-200 For Patients Who Are Unfit for Radical Cystectomy

This Phase 1b trial is evaluating TAR-200 in patients with MIBC who are unfit for radical cystectomy.

TARIS is investigating TAR-200 in combination with Opdivo® (nivolumab), as part of a clinical collaboration with Bristol-Myers Squibb. This Phase 1b trial is evaluating the combination in patients with MIBC who are scheduled for radical cystectomy.